ANI Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ANI Pharmaceuticals
ANIP Stock  USD 78.94  0.48  0.60%   
Analyzing historical trends in various income statement and balance sheet accounts from ANI Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ANI Pharmaceuticals' valuation are summarized below:
Gross Profit
502.3 M
Profit Margin
0.0491
Market Capitalization
1.8 B
Enterprise Value Revenue
2.5659
Revenue
826.9 M
There are currently one hundred twenty fundamental signals for ANI Pharmaceuticals that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate ANI Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/03/2026, Market Cap is likely to grow to about 634.8 M, while Enterprise Value is likely to drop slightly above 99.1 M.

ANI Pharmaceuticals Total Revenue

741.86 Million

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 81.8 M, Interest Expense of 21.3 M or Selling General Administrative of 301.4 M, as well as many indicators such as Price To Sales Ratio of 1.9, Dividend Yield of 0.0012 or PTB Ratio of 2.72. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ANI Stock
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

ANI Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.6 B1.5 B560.5 M
Slightly volatile
Other Current Liabilities159.5 M151.9 M51.7 M
Slightly volatile
Total Current Liabilities233.9 M222.7 M82.8 M
Slightly volatile
Total Stockholder Equity517.4 M492.8 M232.5 M
Slightly volatile
Property Plant And Equipment Net68.7 M65.4 M29.5 M
Slightly volatile
Accounts Payable55.1 M52.5 M17.3 M
Slightly volatile
Cash174.9 M166.6 M85.7 M
Slightly volatile
Non Current Assets Total912.9 M869.4 M312 M
Slightly volatile
Cash And Short Term Investments182.5 M173.8 M87 M
Slightly volatile
Common Stock Total Equity85590031.9 M
Slightly volatile
Common Stock Shares Outstanding23.3 M22.2 M12.6 M
Slightly volatile
Liabilities And Stockholders Equity1.6 B1.5 B560.5 M
Slightly volatile
Other Current Assets21.7 M20.7 M9.4 M
Slightly volatile
Total Liabilities1 B983.4 M327.9 M
Slightly volatile
Property Plant And Equipment Gross122.9 M117 M43.6 M
Slightly volatile
Total Current Assets637.2 M606.8 M248.4 M
Slightly volatile
Common Stock1.7 K1.8 K31.9 M
Slightly volatile
Other Stockholder Equity602.1 M573.4 M255 M
Slightly volatile
Short and Long Term Debt Total753.6 M717.7 M246.6 M
Slightly volatile
Short Term Debt10 M10.5 M31.3 M
Pretty Stable
Current Deferred Revenue39.2 M37.4 M16 M
Slightly volatile
Non Currrent Assets Other14.8 M14.1 M6.1 M
Slightly volatile
Non Current Liabilities Total798.7 M760.7 M258.2 M
Slightly volatile
Net Receivables267.7 M255 M94.8 M
Slightly volatile
Long Term Debt Total114.2 M202.2 M128 M
Slightly volatile
Long Term Investments3.8 M3.9 M3.5 M
Slightly volatile
Property Plant Equipment52.2 M49.7 M26.7 M
Slightly volatile
Capital Surpluse237.5 M464.5 M231.6 M
Slightly volatile
Other Liabilities42.3 M40.3 M13.2 M
Slightly volatile
Short and Long Term Debt7.8 M8.3 M55.1 M
Slightly volatile
Deferred Long Term Asset Charges22.4 M32.2 M20.9 M
Slightly volatile
Net Invested Capital619.3 M1.2 B525.8 M
Slightly volatile
Capital Stock15.6 M28.6 M8.4 M
Slightly volatile
Warrants19.9 M22.4 M24.4 M
Slightly volatile

ANI Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization81.8 M77.9 M34.1 M
Slightly volatile
Selling General Administrative301.4 M287.1 M88 M
Slightly volatile
Total Revenue741.9 M706.5 M245.3 M
Slightly volatile
Other Operating Expenses741.2 M705.9 M242.8 M
Slightly volatile
Research Development53.8 M51.3 M20.6 M
Slightly volatile
Total Operating Expenses439 M418.1 M145.9 M
Slightly volatile
Discontinued Operations156 K175.5 K191.6 K
Slightly volatile
Non Recurring3.8 M5.2 M5 M
Pretty Stable
Interest Income13.7 M14.9 M12.4 M
Slightly volatile
Reconciled Depreciation52.7 M77.9 M41.7 M
Slightly volatile

ANI Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow267 M254.3 M90 M
Slightly volatile
Depreciation81.8 M77.9 M34.1 M
Slightly volatile
Capital Expenditures20.8 M19.5 M32.3 M
Very volatile
End Period Cash Flow175 M166.6 M87.5 M
Slightly volatile
Stock Based Compensation17.7 M26.4 M10.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.92.01000
Slightly volatile
Dividend Yield0.00120.00147.0E-4
Slightly volatile
PTB Ratio2.722.8748.7592
Slightly volatile
Days Sales Outstanding101119146
Slightly volatile
Book Value Per Share21.425.5116.5768
Slightly volatile
Average Payables1.1 M1.9 M1.9 M
Pretty Stable
Stock Based Compensation To Revenue0.05220.05490.2239
Slightly volatile
Capex To Depreciation0.210.232.178
Slightly volatile
PB Ratio2.722.8748.7592
Slightly volatile
Inventory Turnover1.962.11.9807
Slightly volatile
Days Of Inventory On Hand183180209
Slightly volatile
Sales General And Administrative To Revenue0.240.251.8953
Slightly volatile
Research And Ddevelopement To Revenue0.07930.08347.1261
Slightly volatile
Capex To Revenue0.03010.03170.3872
Slightly volatile
Cash Per Share17.479.07.8984
Very volatile
Intangibles To Total Assets0.280.420.3125
Slightly volatile
Current Ratio2.983.135.1039
Slightly volatile
Receivables Turnover3.033.192.6382
Pretty Stable
Shareholders Equity Per Share21.425.5116.5768
Slightly volatile
Debt To Equity1.381.310.841
Slightly volatile
Capex Per Share1.340.792.641
Very volatile
Average Receivables35.3 K37.2 K340 K
Slightly volatile
Revenue Per Share30.0528.6214.7874
Slightly volatile
Interest Debt Per Share31.3929.915.7795
Slightly volatile
Debt To Assets0.30.440.3688
Slightly volatile
Graham Number24.8528.0921.1993
Pretty Stable
Operating Cycle234298328
Slightly volatile
Price Book Value Ratio2.722.8748.7592
Slightly volatile
Company Equity Multiplier1.372.71.9692
Slightly volatile
Long Term Debt To Capitalization0.350.530.4379
Pretty Stable
Total Debt To Capitalization0.340.530.421
Slightly volatile
Debt Equity Ratio1.381.310.841
Slightly volatile
Quick Ratio2.22.324.4215
Slightly volatile
Cash Ratio0.820.863.0792
Slightly volatile
Days Of Inventory Outstanding183180209
Slightly volatile
Days Of Sales Outstanding101119146
Slightly volatile
Price To Book Ratio2.722.8748.7592
Slightly volatile
Fixed Asset Turnover11.0412.437.9426
Slightly volatile
Debt Ratio0.30.440.3688
Slightly volatile
Price Sales Ratio1.92.01000
Slightly volatile
Asset Turnover0.220.430.3424
Slightly volatile
Price Fair Value2.722.8748.7592
Slightly volatile

ANI Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap634.8 M604.6 M543.9 M
Very volatile

ANI Fundamental Market Drivers

Forward Price Earnings9.2678
Cash And Short Term Investments151.2 M

ANI Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue37.4 M39.2 M
Total Revenue706.5 M741.9 M
Cost Of Revenue287.7 M302.1 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.25  0.24 
Research And Ddevelopement To Revenue 0.08  0.08 
Capex To Revenue 0.03  0.03 
Revenue Per Share 28.62  30.05 

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against ANI Stock

  0.89JNJ Johnson JohnsonPairCorr
  0.87MRK Merck CompanyPairCorr
  0.85AZN AstraZeneca PLC ADRPairCorr
  0.79GSK GlaxoSmithKline PLC ADRPairCorr
  0.78BMY Bristol Myers SquibbPairCorr
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY